Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
Cancer Chemother Pharmacol
    June 2021
  1. HUA J, Zhang Z, Zhang L, Sun Y, et al
    UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells.
    Cancer Chemother Pharmacol. 2021 Jun 19. pii: 10.1007/s00280-021-04303.
    >> Share

  2. HELSBY N, Yong M, Burns K, Findlay M, et al
    Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.
    Cancer Chemother Pharmacol. 2021 Jun 10. pii: 10.1007/s00280-021-04307.
    >> Share

  3. WANG B, Deng R, Hennig S, Badovinac Crnjevic T, et al
    Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
    Cancer Chemother Pharmacol. 2021 Jun 9. pii: 10.1007/s00280-021-04296.
    >> Share

    May 2021
  4. PATTARAWAT P, Hunt JT, Poloway J, Archibald CJ, et al
    A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.
    Cancer Chemother Pharmacol. 2021 May 27. pii: 10.1007/s00280-021-04298.
    >> Share

    April 2021
  5. PAPAGEORGIOU C, Andrikopoulou A, Dimopoulos MA, Zagouri F, et al
    Cardiovascular toxicity of breast cancer treatment: an update.
    Cancer Chemother Pharmacol. 2021 Apr 17. pii: 10.1007/s00280-021-04254.
    >> Share

  6. XU B, Li H, Zhang Q, Sun W, et al
    Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women.
    Cancer Chemother Pharmacol. 2021 Apr 9. pii: 10.1007/s00280-021-04263.
    >> Share

    March 2021
  7. TURIJAN-ESPINOZA E, Ruiz-Rodriguez VM, Uresti-Rivera EE, Martinez-Leija E, et al
    Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients.
    Cancer Chemother Pharmacol. 2021 Mar 19. pii: 10.1007/s00280-021-04244.
    >> Share

    February 2021
  8. LYNCE F, Williams JT, Regan MM, Bunnell CA, et al
    Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.
    Cancer Chemother Pharmacol. 2021 Feb 14. pii: 10.1007/s00280-021-04245.
    >> Share

  9. YI X, Lou L, Wang J, Xiong J, et al
    Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway.
    Cancer Chemother Pharmacol. 2021 Feb 5. pii: 10.1007/s00280-021-04238.
    >> Share

    January 2021
  10. SPILIOTAKI M, Kallergi G, Nikolaou C, Xenidis N, et al
    Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(-) breast cancer receiving salvage treatment with everolimus/exemestane.
    Cancer Chemother Pharmacol. 2021 Jan 29. pii: 10.1007/s00280-020-04227.
    >> Share

  11. MEHRAJ U, Dar AH, Wani NA, Mir MA, et al
    Tumor microenvironment promotes breast cancer chemoresistance.
    Cancer Chemother Pharmacol. 2021 Jan 9. pii: 10.1007/s00280-020-04222.
    >> Share

  12. LUNAR N, Etienne-Grimaldi MC, Macaire P, Thomas F, et al
    Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients.
    Cancer Chemother Pharmacol. 2021 Jan 2. pii: 10.1007/s00280-020-04208.
    >> Share

    November 2020
  13. XU Y, Liao S, Wang L, Wang Y, et al
    Galeterone sensitizes breast cancer to chemotherapy via targeting MNK/eIF4E and beta-catenin.
    Cancer Chemother Pharmacol. 2020 Nov 7. pii: 10.1007/s00280-020-04195.
    >> Share

    October 2020
  14. TSUJI D, Matsumoto M, Kawasaki Y, Kim YL, et al
    Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy.
    Cancer Chemother Pharmacol. 2020 Oct 24. pii: 10.1007/s00280-020-04177.
    >> Share

  15. ZHANG Z, Zhang L, Yu G, Sun Z, et al
    Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Cancer Chemother Pharmacol. 2020 Oct 17. pii: 10.1007/s00280-020-04168.
    >> Share

    June 2020
  16. TSUKIOKI T, Shien T, Tanaka T, Suzuki Y, et al
    Influences of preoperative metformin on immunological factors in early breast cancer.
    Cancer Chemother Pharmacol. 2020 Jun 12. pii: 10.1007/s00280-020-04092.
    >> Share

  17. JUAREZ M, Schcolnik-Cabrera A, Dominguez-Gomez G, Chavez-Blanco A, et al
    Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug.
    Cancer Chemother Pharmacol. 2020;85:1153-1163.
    >> Share

    May 2020
  18. SANCHEZ-SPITMAN AB, Moes DAR, Swen JJ, Dezentje VO, et al
    Exposure-response analysis of endoxifen serum concentrations in early-breast cancer.
    Cancer Chemother Pharmacol. 2020 May 29. pii: 10.1007/s00280-020-04089.
    >> Share

    April 2020
  19. YANG H, Lu Y, Zheng Y, Yu X, et al
    Expression of Concern: shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells.
    Cancer Chemother Pharmacol. 2020 Apr 10. pii: 10.1007/s00280-020-04044.
    >> Share

  20. TOLCHER AW, Kurzrock R, Valero V, Gonzalez R, et al
    Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.
    Cancer Chemother Pharmacol. 2020;85:673-683.
    >> Share

    March 2020
  21. MORTIMER JE, Kruper L, Jung J, Wong L, et al
    Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab.
    Cancer Chemother Pharmacol. 2020;85:501-507.
    >> Share

    February 2020
  22. POTHURI B, Brodsky AL, Sparano JA, Blank SV, et al
    Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
    Cancer Chemother Pharmacol. 2020 Feb 13. pii: 10.1007/s00280-020-04030.
    >> Share

  23. TONRA JR, Lloyd GK, Mohanlal R, Huang L, et al
    Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies.
    Cancer Chemother Pharmacol. 2020;85:461-468.
    >> Share

    January 2020
  24. LIANG Z, Feng A, Shim H
    MicroRNA-30c-regulated HDAC9 mediates chemoresistance of breast cancer.
    Cancer Chemother Pharmacol. 2020 Jan 6. pii: 10.1007/s00280-019-04024.
    >> Share

    December 2019
  25. PATTARAWAT P, Wallace S, Pfisterer B, Odoi A, et al
    Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development.
    Cancer Chemother Pharmacol. 2019 Dec 21. pii: 10.1007/s00280-019-04013.
    >> Share

  26. ZHAO Y, Wei L, Liu J, Li F, et al
    Chemoresistance was correlated with elevated expression and activity of indoleamine 2,3-dioxygenase in breast cancer.
    Cancer Chemother Pharmacol. 2019 Dec 16. pii: 10.1007/s00280-019-04009.
    >> Share

  27. HUANG L, Wang X, Zhou L, Di L, et al
    Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer.
    Cancer Chemother Pharmacol. 2019 Dec 14. pii: 10.1007/s00280-019-04000.
    >> Share

    November 2019
  28. ROSSI L, Verrico M, Tomao S, Ricci F, et al
    Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.
    Cancer Chemother Pharmacol. 2019 Nov 21. pii: 10.1007/s00280-019-03981.
    >> Share

  29. XU Z, Luo F, Wang Y, Zou BS, et al
    Cognitive impairments in breast cancer survivors treated with chemotherapy: a study based on event-related potentials.
    Cancer Chemother Pharmacol. 2019 Nov 19. pii: 10.1007/s00280-019-03994.
    >> Share

    October 2019
  30. SENTURK M, Ercan F, Yalcin S
    The secondary metabolites produced by Lactobacillus plantarum downregulate BCL-2 and BUFFY genes on breast cancer cell line and model organism Drosophila melanogaster: molecular docking approach.
    Cancer Chemother Pharmacol. 2019 Oct 31. pii: 10.1007/s00280-019-03978.
    >> Share

    September 2019
  31. SUN Y, Lin X, Aske JC, Ye P, et al
    Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.
    Cancer Chemother Pharmacol. 2019 Sep 20. pii: 10.1007/s00280-019-03962.
    >> Share

  32. CRUCITTA S, Restante G, Del Re M, Bertolini I, et al
    Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy.
    Cancer Chemother Pharmacol. 2019 Sep 16. pii: 10.1007/s00280-019-03933.
    >> Share

  33. SUN Y, Yan L, Guo J, Shao J, et al
    Downregulation of SRSF3 by antisense oligonucleotides sensitizes oral squamous cell carcinoma and breast cancer cells to paclitaxel treatment.
    Cancer Chemother Pharmacol. 2019 Sep 12. pii: 10.1007/s00280-019-03945.
    >> Share

  34. SAKURADA T, Bando S, Zamami Y, Takechi K, et al
    Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.
    Cancer Chemother Pharmacol. 2019 Sep 9. pii: 10.1007/s00280-019-03948.
    >> Share

  35. LIU B, Su F, Lv X, Zhang W, et al
    Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab.
    Cancer Chemother Pharmacol. 2019 Sep 4. pii: 10.1007/s00280-019-03937.
    >> Share

    August 2019
  36. NUTHALAPATI S, Stodtmann S, Shepherd SP, Ratajczak CK, et al
    Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients.
    Cancer Chemother Pharmacol. 2019 Aug 29. pii: 10.1007/s00280-019-03930.
    >> Share

  37. ESTEVA FJ, Baranau YV, Baryash V, Manikhas A, et al
    Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial.
    Cancer Chemother Pharmacol. 2019 Aug 19. pii: 10.1007/s00280-019-03920.
    >> Share

  38. XING M, Wang J, Yang Q, Wang Y, et al
    FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer.
    Cancer Chemother Pharmacol. 2019 Aug 19. pii: 10.1007/s00280-019-03923.
    >> Share

  39. MENG L, Huang L, Xu Y, Zhang W, et al
    Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin.
    Cancer Chemother Pharmacol. 2019 Aug 3. pii: 10.1007/s00280-019-03909.
    >> Share

    July 2019
  40. PEER CJ, Schmidt KT, Kindrick JD, Eisner JR, et al
    A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.
    Cancer Chemother Pharmacol. 2019 Jul 31. pii: 10.1007/s00280-019-03908.
    >> Share

  41. FRAGUAS-SANCHEZ AI, Martin-Sabroso C, Fernandez-Carballido A, Torres-Suarez AI, et al
    Current status of nanomedicine in the chemotherapy of breast cancer.
    Cancer Chemother Pharmacol. 2019 Jul 31. pii: 10.1007/s00280-019-03910.
    >> Share

  42. CAO L, Xiang G, Liu F, Xu C, et al
    A high AR:ERalpha or PDEF:ERalpha ratio predicts a sub-optimal response to tamoxifen therapy in ERalpha-positive breast cancer.
    Cancer Chemother Pharmacol. 2019 Jul 11. pii: 10.1007/s00280-019-03891.
    >> Share

  43. CHEN X, Li C, Ewesuedo R, Yin D, et al
    Correction to: Population pharmacokinetics of PF05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin((R))) in patients with HER2positive metastatic breast cancer.
    Cancer Chemother Pharmacol. 2019 Jul 10. pii: 10.1007/s00280-019-03890.
    >> Share

    June 2019
  44. KOTAKE M, Imai H, Kaira K, Fujisawa T, et al
    Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study.
    Cancer Chemother Pharmacol. 2019 Jun 27. pii: 10.1007/s00280-019-03897.
    >> Share

    May 2019
  45. LU D, Li C, Riggs M, Polhamus D, et al
    Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
    Cancer Chemother Pharmacol. 2019 May 17. pii: 10.1007/s00280-019-03852.
    >> Share

  46. CHEN X, Li C, Ewesuedo R, Yin D, et al
    Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin((R))) in patients with HER2-positive metastatic breast cancer.
    Cancer Chemother Pharmacol. 2019 May 3. pii: 10.1007/s00280-019-03850.
    >> Share

    April 2019
  47. KIRSCHBROWN WP, Kagedal M, Wang B, Lindbom L, et al
    Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.
    Cancer Chemother Pharmacol. 2019 Apr 11. pii: 10.1007/s00280-019-03826.
    >> Share

  48. ARAZ M, Karaagac M, Korkmaz L, Koral L, et al
    Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study.
    Cancer Chemother Pharmacol. 2019 Apr 8. pii: 10.1007/s00280-019-03831.
    >> Share

  49. TANAKA S, Matsunami N, Morishima H, Oda N, et al
    De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer.
    Cancer Chemother Pharmacol. 2019 Apr 8. pii: 10.1007/s00280-019-03836.
    >> Share

    January 2019
  50. CAMPONE M, Bachelot T, Penault-Llorca F, Pallis A, et al
    A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer.
    Cancer Chemother Pharmacol. 2019 Jan 25. pii: 10.1007/s00280-018-03765.
    >> Share

  51. NGUYEN TT, Angeli E, Darrouzain F, Nguyen QT, et al
    A successful compartmental approach for the treatment of breast cancer brain metastases.
    Cancer Chemother Pharmacol. 2019 Jan 5. pii: 10.1007/s00280-018-3752.
    >> Share

    November 2018
  52. CAZZANIGA ME, Ciruelos E, Fabi A, Garcia-Saenz J, et al
    Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH project.
    Cancer Chemother Pharmacol. 2018 Nov 20. pii: 10.1007/s00280-018-3717.
    >> Share

    October 2018
  53. ESIN E, Oksuzoglu B, Bilici A, Cicin I, et al
    Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes.
    Cancer Chemother Pharmacol. 2018 Oct 30. pii: 10.1007/s00280-018-3712.
    >> Share

  54. BAI Y, Wu HW, Zhang YH
    Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis.
    Cancer Chemother Pharmacol. 2018 Oct 24. pii: 10.1007/s00280-018-3703.
    >> Share

    July 2018
  55. HUANG W, Liu J, Zeng Y, Wu F, et al
    Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
    Cancer Chemother Pharmacol. 2018 Jul 24. pii: 10.1007/s00280-018-3639.
    >> Share

    June 2018
  56. XU C, Ravva P, Dang JS, Laurent J, et al
    A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.
    Cancer Chemother Pharmacol. 2018 Jun 18. pii: 10.1007/s00280-018-3621.
    >> Share

  57. RODON J, Perez-Fidalgo A, Krop IE, Burris H, et al
    Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.
    Cancer Chemother Pharmacol. 2018 Jun 7. pii: 10.1007/s00280-018-3610.
    >> Share

  58. IIZUMI S, Shimomura A, Shimoi T, Sudo K, et al
    Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study.
    Cancer Chemother Pharmacol. 2018 Jun 5. pii: 10.1007/s00280-018-3617.
    >> Share

    May 2018
  59. HUANG JF, Wen CJ, Zhao GZ, Dai Y, et al
    Overexpression of ABCB4 contributes to acquired doxorubicin resistance in breast cancer cells in vitro.
    Cancer Chemother Pharmacol. 2018 May 18. pii: 10.1007/s00280-018-3603.
    >> Share

  60. LEUNG HW, Ko CH, Yue GG, Herr I, et al
    The natural agent 4-vinylphenol targets metastasis and stemness features in breast cancer stem-like cells.
    Cancer Chemother Pharmacol. 2018 May 18. pii: 10.1007/s00280-018-3601.
    >> Share

  61. LITVIAKOV N, Tsyganov M, Larionova I, Ibragimova M, et al
    Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy.
    Cancer Chemother Pharmacol. 2018 May 4. pii: 10.1007/s00280-018-3594.
    >> Share

    March 2018
  62. KIMURA K, Iwamoto M, Tanaka S, Yamamoto D, et al
    A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
    Cancer Chemother Pharmacol. 2018 Mar 28. pii: 10.1007/s00280-018-3567.
    >> Share

    February 2018
  63. CITI V, Del Re M, Martelli A, Calderone V, et al
    Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.
    Cancer Chemother Pharmacol. 2018 Feb 23. pii: 10.1007/s00280-018-3543.
    >> Share

  64. NAKAYAMA T, Sagara Y, Takashima T, Matsunami N, et al
    Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC).
    Cancer Chemother Pharmacol. 2018 Feb 21. pii: 10.1007/s00280-018-3544.
    >> Share

  65. LIU Z, Tao Z, Zhang Q, Wan S, et al
    YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells.
    Cancer Chemother Pharmacol. 2018 Feb 1. pii: 10.1007/s00280-018-3535.
    >> Share

    December 2017
  66. ZHOU X, Qiao G, Wang X, Song Q, et al
    CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.
    Cancer Chemother Pharmacol. 2017 Dec 14. pii: 10.1007/s00280-017-3500.
    >> Share

  67. SHIEN T, Doihara H, Sato N, Anan K, et al
    Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study.
    Cancer Chemother Pharmacol. 2017 Dec 1. pii: 10.1007/s00280-017-3491.
    >> Share

    October 2017
  68. LI C, Wang B, Chen SC, Wada R, et al
    Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
    Cancer Chemother Pharmacol. 2017 Oct 11. doi: 10.1007/s00280-017-3440.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016